Last updated on July 2020

Live Biotherapeutic Product MRx0518 and Pembrolizumab Combination Study in Solid Tumors


Brief description of study

This is an open label, safety and preliminary efficacy study of MRx0518 in combination with pembrolizumab in patients with solid tumours (non small cell lung cancer, renal cell carcinoma, bladder cancer or melanoma).

Subjects will be treated with IV pembrolizumab every 3 weeks and 1 capsule twice daily of MRx0518. Treatment will continue as long as clinically relevant, until disease progression, unacceptable AEs or withdrawal of consent up to a maximum of 35 cycles (approx. 2 years).

Clinical Study Identifier: NCT03637803

Find a site near you

Start Over

MD Anderson Cancer Center

Houston, TX United States
  Connect »

Summit Cancer Center

Spokane, WA United States
  Connect »

UPMC Hillman Cancer Center

Pittsburgh, PA United States
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.